Navigation Links
Significant Advance in Treatment of Breast Cancer Reported

In what may be a significant advance for the treatment of breast cancer, researchers have discovered they can more effectively wipe out diseased tissue when standard chemotherapy is combined with a drug //that shuts down certain molecular pathways involved in causing cancer.

In a multicenter clinical trial reported in the Jully, 2006 issue of the Journal of Clinical Oncology, women with locally advanced breast cancer were given an oral medication that inhibits an enzyme called farnesyltransferase, in addition to routine chemotherapy, before undergoing surgery. Farnesyltransferase is required to set in motion a series of molecular events involved in the development of cancer.

Analysis of the breast tissue taken at surgery showed no signs of cancer in a third of the patients.

"The findings are extremely encouraging," said Dr. Joseph Sparano, lead author of the study and director of the Breast Evaluation Center at the Montefiore-Einstein Cancer Center. "Eradication of cancer cells in breast tissue is a short-term endpoint that translates into a greater chance of cure in the long term. This combination of therapies definitely looks promising, and we are moving ahead with larger trials to confirm our results.”

The study included 21 women with locally advanced breast cancer who were considered suboptimal candidates for surgery because of the advanced stage of their disease. They received standard chemotherapy, doxorubicin and cyclophosphamide, given intravenously once every two weeks for four treatments. After each chemotherapy treatment, they also received 200 mg of tipifarnib, which inhibits farnesyltransferase, twice a day for six days. All patients then underwent a mastectomy or a lumpectomy.

Pathological analyses of breast tissue retrieved from the surgeries showed no cancerous tissue in seven patients, or 33 percent of the women who received the treatment, compared with 5 to 10 percent expected with chemothe rapy alone.

The researchers also demonstrated that tipifarnib inhibited farnesyltransferase in tumor tissue by an average of 90 percent. Farnesyltransferase is essential for activating proteins, such as one called Ras, that contribute to the growth of cancer cells.

"This important study suggests that the proliferation and survival of breast tumor cells from one third of the patients in our study depended on proteins that were activated by farnesyltransferase," said Dr. Said Sebti, coauthor of the study and associate director of the Moffitt Research Institute in Tampa, Florida.

"We believe that by switching off the farnesylation-dependent pathways we made the chemotherapy much more effective" said Dr. Sparano. "Our next step will be to combine tipifarnib with other types of standard chemotherapy in order to push the response rate even higher, and perform randomized trials that provide more definitive proof of the benefits of this treatment."

The trial was performed by the New York Cancer Consortium, a multicenter clinical trials group funded by the National Cancer Institute to evaluate the newest and most promising cancer treatments. Montefiore Medical Center is the lead institution for this group. Each year, approximately 200 patients are enrolled in clinical trials conducted by the Consortium. The work was also partially funded by a grant from the National Cancer Institute to Dr. Septi.

Montefiore Medical Center, The University Hospital and Academic Medical Center for the Albert Einstein College of Medicine, ranks among the top one percent of all US hospitals based on its investments in medical innovation and cutting-edge technology.

(Source: Newswise)
'"/>




Related medicine news :

1. Inhaled Corticosteroids Found To Have No Significant Effect On COPD
2. A Little Weight Loss Found To Make A Significant Difference In Men
3. New Drug Shows Significant Improvement In HIV-related Heart Condition
4. Patient Negligence - Significant Problem In The Early Detection Of Breast Cancer
5. Kidney Disease, More Significant Risk Factor For Heart Disease Than Obesity
6. Silicone Implants Make No Significant Difference To Breast Cancer Survivors
7. Biomarkers Could Prove Significant In Understanding Aging Process
8. Smoke From Cooking Fuels Cause A Significant Number Of Death Worldwide
9. Increased Nighttime BP, a Significant Predictor of Congestive Heart Failure
10. Significant role of genetics in drug abuse, Norwegian study
11. Significant Increase In Heart Diseases Found In Older People Living Alone
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
(Date:6/23/2016)... 23, 2016  Guerbet announced today that it has ... Horizon Award . One of 12 suppliers ... for its support of Premier members through exceptional local ... and commitment to lower costs. ... of our outstanding customer service from Premier," says ...
(Date:6/23/2016)... , June 23, 2016  Experian ... integrating and transforming the patient payment and ... several innovative new products and services that ... its revenue cycle offerings. These award-winning solutions ... efficient workflows, remain compliant in an ever-changing ...
Breaking Medicine Technology: